Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention | Zendy

Marian Moazez J. | Zendy; Alli Oluseun | Zendy; Al Solaiman Firas | Zendy; Brott Brigitta C. | Zendy; Sasse Mark | Zendy; Leesar Tara | Zendy; Prabhu Sumanth D. | Zendy; Leesar Massoud A. | Zendy

Open Access

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Author(s) -

Marian Moazez J.,

Alli Oluseun,

Al Solaiman Firas,

Brott Brigitta C.,

Sasse Mark,

Leesar Tara,

Prabhu Sumanth D.,

Leesar Massoud A.

Publication year - 2017

Publication title -

journal of the american heart association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.494

H-Index - 85

ISSN - 2047-9980

DOI - 10.1161/jaha.117.005562

Subject(s) - eptifibatide , medicine , ticagrelor , percutaneous coronary intervention , bolus (digestion) , p2y12 , tirofiban , cardiology , myocardial infarction , anesthesia , platelet aggregation inhibitor , platelet

In patients with non-ST-segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y 12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa inhibitors are still needed. Ticagrelor and eptifibatide bolus only may maximally inhibit platelet aggregation and decrease bleeding, but IPA with ticagrelor and eptifibatide bolus versus 2-hour infusion is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research